CSIMarket Company Name, Ticker, Competitors, else..


Supernus Pharmaceuticals inc   (NASDAQ: SUPN)
Other Ticker:  
 

Supernus Pharmaceuticals inc

SUPN's Fundamental analysis



Looking into Supernus Pharmaceuticals Inc growth rates, revenue grew by 13.18 % in IV. Quarter 2024 from the same quarter a year ago. Ranking at No. 1217

Major Pharmaceutical Preparations industry recorded growth of revenues by 11.85 %

Supernus Pharmaceuticals Inc realized net income compared to net loss a year ago in IV. Quarter 2024

• More on SUPN's Growth


Supernus Pharmaceuticals Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Supernus Pharmaceuticals Inc PEG ratio is at 0.09 Supernus Pharmaceuticals Inc realized cash reduction of $ -0.1 per share in trailing twelve-month period.
Company
23.93
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 2.66.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.1.


• More on SUPN's Valuation
 
 Total Debt (Millions $) -
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 1,015,057
 Net Income/Employee (TTM) $ 113,290
 Receivable Turnover (TTM) 4.5
 Tangible Book Value (Per Share $) 7.09

Supernus Pharmaceuticals Inc
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Supernus Pharmaceuticals Inc PEG ratio is at 0.09 Supernus Pharmaceuticals Inc realized cash outflow of $ -0.1per share in trailing twelve-month period.
Company
23.93
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 2.66.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.1.

Supernus Pharmaceuticals Inc Price to Book Ratio is at 1.7 lower than Industry Avg. of 77.28. and higher than S&P 500 Avg. of 0.01

• More on SUPN's Valuation

•  Market Capitalization (Millions $) 1,760
•  Shares Outstanding (Millions) 56
•  Employees 652
•  Revenues (TTM) (Millions $) 662
•  Net Income (TTM) (Millions $) 74
•  Cash Flow (TTM) (Millions $) -6
•  Capital Exp. (TTM) (Millions $) -1
•  Total Debt (Millions $) -
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 1,015,057
•  Net Income/Employee(TTM) $ 113,290
•  Receivable Turnover Ratio (TTM) 4.5
•  Tangible Book Value (Per Share $) 7.09

•  Market Capitalization (Millions $) 1,760
•  Shares Outstanding (Millions) 56
•  Employees 652
•  Revenues (TTM) (Millions $) 662
•  Net Income (TTM) (Millions $) 74
•  Cash Flow (TTM) (Millions $) -6
•  Capital Exp. (TTM) (Millions $) -1


    SUPN's Profitability Comparisons
Supernus Pharmaceuticals Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in IV. Quarter 2024 to 12.29 % from 23.25 % in III. Quarter.

Supernus Pharmaceuticals Inc net profit margin of 8.8 % is currently ranking no. 48 in Major Pharmaceutical Preparations industry, ranking no. 130 in Healthcare sector and number 1480 in S&P 500.


Profitability by Segment
Total 21.91 %



  Ratio
•   Capital Ratio (MRQ) 5.55
•  Total Debt to Equity (MRQ) -
•  Tangible Leverage Ratio (MRQ) 0.33
•  Asset Turnover Ratio (TTM) 0.5
•  Inventory Turnover Ratio (TTM) 1.19



Supernus Pharmaceuticals Inc faced margin deterioration, primarily through cost pressure. Operating Margin fell in IV. Quarter 2024 to 12.29 % from 23.25 % in III. Quarter.

Supernus Pharmaceuticals Inc net profit margin of 8.8 % is currently ranking no. 48 in Major Pharmaceutical Preparations industry, ranking no. 130 in Healthcare sector and number 1480 in S&P 500.

• More on SUPN's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com